Drugs / AN2025
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04975958 | Sep 2021 → Jan 2025 | — | Adlai Nortye Biopharma Co., Ltd. | Completed | No outcome recorded |
Press releases naming this drug 4 releases
| Date | Issuer | Release |
|---|---|---|
| 2025-05-30 | Nippon Kayaku Co., Ltd. | 抗PD-1/PD-L1療法後に進行した再発性または転移性頭頸部扁平上皮がんに対するパクリタキセルとブパルリシブ（開発コード：AN2025）の併用療法を評価する第Ⅲ相BURAN試験のトップライン結果のお知らせ nipponkayaku.co.jp ↗ |
| 2021-09-07 | Adlai Nortye Biopharma Co., Ltd. | Adlai Nortye Announces First Patient Dosed in Phase Ia Clinical Trial of AN2025 and AN0025 in Combination with atezolizumab for Advanced Solid Tumors adlainortye.com ↗ |
| 2021-04-14 | Adlai Nortye Biopharma Co., Ltd. | Adlai Nortye Announces First Patient Dosed in Global Phase III Clinical Trial of Buparlisib (AN2025) in Combination with Paclitaxel for the Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma adlainortye.com ↗ |
| 2019-03-14 | Adlai Nortye Biopharma Co., Ltd. | Adlai Nortye Presents Supportive Non-Clinical Data of Buparlisib (AN2025) at the 7th ICHNO adlainortye.com ↗ |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AN2025 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04975958 ↗ |